StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research report released on Monday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Stock Performance
Acorda Therapeutics has a twelve month low of $0.61 and a twelve month high of $24.20. The firm has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. The firm has a fifty day moving average price of $10.27 and a two-hundred day moving average price of $11.87. The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26.
About Acorda Therapeutics
See Also
- Five stocks we like better than Acorda Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is the NASDAQ Stock Exchange?
- Generac Powers Ahead on the Electrification Mega-Trend
- Business Services Stocks Investing
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.